rnf19b Antibody

What is RNF19B and what are its alternative names in scientific literature?

RNF19B, also designated as Natural Killer Lytic-Associated Molecule (NKLAM), is a member of a small family of E3 ubiquitin ligases characterized by a cysteine-rich RING-IBR-RING (RBR) domain. Other synonyms in scientific literature include IBR domain-containing protein 3 and E3 ubiquitin-protein ligase RNF19B. This protein plays a critical role in innate immune responses, particularly in natural killer (NK) cells and macrophages, where it mediates maximal killing activity and cytokine production .

What is the structure and cellular localization of RNF19B protein?

The human canonical RNF19B protein consists of 732 amino acid residues with a molecular mass of 77.9 kDa. The protein features a characteristic RBR domain structure consisting of a C3HC4 RING domain (RING1), followed by an In-Between RING (IBR), and another RING domain (RING2) containing a conserved catalytic cysteine (C302) that is critical for its ligase activity. RNF19B also contains two transmembrane domains that anchor the protein, and two intrinsically disordered regions (IDRs) - one at the N-terminal end (first 100 amino acids) and another larger one at the C-terminal end. In terms of subcellular localization, RNF19B is found in the endoplasmic reticulum and cytoplasm. In NK cells specifically, RNF19B localizes to the membranes of cytolytic granules upon activation .

In which cell types is RNF19B predominantly expressed?

RNF19B is notably expressed in cells of the immune system, particularly in natural killer cells, activated macrophages, and cytotoxic T-cells (CD8+ CTLs). Expression has been confirmed in freshly isolated human peripheral blood monocytes, splenic and peritoneal macrophages in mice, and in cytotoxic T lymphocyte clones. Limited data also shows expression in non-immune cells such as testes (associated with ppp1cc) and mouse tracheal epithelial cells when treated with IFNγ .

How is RNF19B expression regulated in immune cells?

RNF19B expression is induced by various cytokines and immune stimuli. In NK cells, which have low baseline levels of RNF19B, expression is rapidly upregulated by interferon beta (IFNβ), with mRNA levels peaking 4-6 hours after stimulation. Other cytokines that promote RNF19B transcription in NK cells include IL-2 (peaking 6-12 hours after stimulation), IL-12, IL-15, and IL-21. In macrophages, IFNγ induces RNF19B expression in a time-dependent manner, with maximal levels reached at 12 hours post-stimulation. Bacterial products like lipopolysaccharide (LPS) can also induce RNF19B expression, with peak levels observed 16 hours after stimulation. The RNF19B promoter contains binding sites for STAT1, STAT4, STAT5, IRF family transcription factors, and NFκB proteins (p50 and p65/RelA), supporting its regulation by both interferon and inflammatory pathways .

What experimental systems are available for studying RNF19B function?

Several experimental systems have been developed to study RNF19B function. Cell-based systems include the human NK clone NK3.3, which can be stimulated with cytokines to upregulate RNF19B expression. Macrophage cell lines like RAW 264.7 and J774, as well as primary bone marrow-derived macrophages (BMDMs), have been used to study RNF19B function in phagocytic cells. For in vivo studies, NKLAM-deficient (knockout) mice have been generated, allowing investigation of RNF19B's role in various immune processes. Molecular tools include antisense oligonucleotides to specifically downregulate RNF19B expression in cell culture systems. The yeast two-hybrid system has also been employed to identify proteins that interact with RNF19B, using its RING domain as bait against a human spleen cell cDNA library .

Which experimental approaches can be used to detect RNF19B protein expression?

Multiple experimental approaches can be used to detect RNF19B protein expression. Western blotting is a widely used application for RNF19B detection using specific antibodies against different regions of the protein (N-terminal, C-terminal, or central regions). Immunofluorescence is another common application for visualizing the subcellular localization of RNF19B. Flow cytometry can be used to measure RNF19B expression levels in specific cell populations. Other methods include ELISA and FLISA for quantitative measurement. For subcellular localization studies, cell fractionation followed by Western blotting has been used to demonstrate RNF19B's association with granule membranes in NK cells. Monoclonal antibodies specifically generated against RNF19B have proven valuable for these detection methods .

What are the optimal conditions for inducing RNF19B expression in laboratory experiments?

For inducing RNF19B expression in laboratory experiments, optimal conditions depend on the cell type being studied. In NK cells, treatment with IFNβ induces rapid transcription and translation of RNF19B, with peak mRNA levels at 4-6 hours post-stimulation. IL-2 treatment also effectively induces RNF19B, with peak expression at 6-12 hours. For macrophages, IFNγ treatment induces maximal RNF19B expression at approximately 12 hours post-stimulation. Combined stimulation with LPS plus IFNγ leads to the largest increase in RNF19B levels in macrophages. In macrophage cell lines (RAW 264.7 and J774), peak expression is observed 16 hours after stimulation with various TLR agonists, including LPS, bacterial products from E. coli or S. aureus, or Poly(I:C). The relatively short half-life of RNF19B mRNA (2.5 hours) should be considered when designing time-course experiments .

What are the recommended controls when studying RNF19B function with antibodies?

When studying RNF19B function using antibodies, several controls are recommended. For specificity validation, NKLAM-deficient cells or tissues derived from knockout mice serve as excellent negative controls. Alternatively, cells treated with RNF19B-specific antisense oligonucleotides can be used as negative controls in experiments where genetic knockouts are not available. For positive controls, cytokine-stimulated NK cells or IFNγ-treated macrophages that express high levels of RNF19B are recommended. When performing co-immunoprecipitation experiments to identify RNF19B-interacting proteins, controls should include immunoprecipitation with isotype-matched irrelevant antibodies. For functional studies of RNF19B's E3 ubiquitin ligase activity, mutation of the conserved catalytic cysteine (C302) in the RING2 domain can serve as a catalytically inactive control .

How can RNF19B antibodies be used to investigate the protein's role in immune cell cytotoxicity?

RNF19B antibodies can be used in several sophisticated approaches to investigate its role in immune cell cytotoxicity. Immunofluorescence microscopy with RNF19B antibodies can visualize its localization to cytolytic granule membranes in activated NK cells and track dynamic changes during the formation of immunological synapses with target cells. For mechanistic studies, antibodies can be used in immunoprecipitation experiments to identify proteins that interact with RNF19B during the cytolytic process. Combined with ubiquitination assays, researchers can identify which proteins are ubiquitinated by RNF19B during cytotoxic events. Time-course experiments tracking RNF19B expression, localization, and associated proteins following NK cell activation can reveal the precise timing of RNF19B's involvement in the cytolytic pathway. In cytotoxicity assays, correlating RNF19B expression levels (detected by flow cytometry with anti-RNF19B antibodies) with killing efficiency can establish quantitative relationships between RNF19B expression and cytotoxic function .

What methodological approaches can resolve contradictory data regarding RNF19B function in different experimental systems?

When faced with contradictory data regarding RNF19B function across different experimental systems, several methodological approaches can help resolve discrepancies. First, researchers should conduct parallel experiments using both primary cells and cell lines to determine if immortalization affects RNF19B function. Species-specific differences should be investigated by comparing human and murine systems directly under identical experimental conditions. Tissue-specific or cell type-specific effects can be addressed using conditional knockout models where RNF19B is deleted only in specific cell populations. For conflicting results regarding RNF19B's role in signaling pathways, phospho-specific antibodies against key signaling molecules should be used alongside RNF19B antibodies to monitor multiple pathway components simultaneously. Single-cell analysis techniques can help determine if contradictory results stem from heterogeneity within cell populations. Finally, for discrepancies in RNF19B's E3 ligase targets, in vitro ubiquitination assays with purified components followed by mass spectrometry can definitively identify substrates and ubiquitination sites .

How can RNF19B antibodies be utilized to study its interaction with E2 ubiquitin-conjugating enzymes?

RNF19B antibodies can be utilized in several experimental approaches to study its interaction with E2 ubiquitin-conjugating enzymes like UbcH7 and UbcH8. Co-immunoprecipitation experiments using RNF19B antibodies can pull down associated E2 enzymes from cell lysates, especially following cytokine stimulation when both RNF19B and UbcH8 are upregulated. Proximity ligation assays (PLA) using antibodies against both RNF19B and specific E2 enzymes can visualize their interactions in situ with subcellular resolution. For domain-specific interaction studies, researchers can use antibodies recognizing different regions of RNF19B in combination with truncation mutants to map the specific domains mediating E2 interaction. In vitro ubiquitination assays using immunopurified RNF19B can test functional interactions with different E2 enzymes. For temporal dynamics of interaction, time-course experiments following NK activation can determine when RNF19B-E2 interactions occur in relation to cytolytic events. Finally, structural studies using purified proteins in combination with domain-specific antibodies can elucidate the conformational changes that occur during E2-E3 interaction .

What experimental designs can determine if RNF19B targets different substrates in different cell types?

To determine if RNF19B targets different substrates in different cell types, several experimental designs using RNF19B antibodies can be employed. Comparative immunoprecipitation followed by mass spectrometry can identify RNF19B-interacting proteins in different cell types (e.g., NK cells versus macrophages). This approach can be enhanced by treating cells with proteasome inhibitors to stabilize ubiquitinated proteins. Cell-type-specific ubiquitinome analysis can compare the global patterns of ubiquitinated proteins in wild-type versus RNF19B-deficient cells of different lineages. For targeted validation of specific substrates, in situ proximity ligation assays using antibodies against RNF19B and putative substrates can confirm interactions in specific cell types. Biochemical fractionation combined with Western blotting can determine if RNF19B localizes to different subcellular compartments in different cell types, potentially accessing distinct substrate pools. Finally, conditional expression systems where RNF19B is expressed in non-native cell types can test if substrate specificity is intrinsic to RNF19B or dependent on the cellular context .

What are the critical factors to consider when selecting RNF19B antibodies for specific applications?

When selecting RNF19B antibodies for specific applications, researchers should consider several critical factors. The epitope location is important - antibodies targeting different regions of RNF19B (N-terminal, C-terminal, or RBR domain) may perform differently depending on protein conformation and interaction with other molecules. Species reactivity must match the experimental system; available antibodies can react with human, mouse, rat, rabbit, horse, and pig RNF19B. The application compatibility should be verified, as some antibodies perform well in Western blot but not in immunoprecipitation or immunofluorescence. For detecting specific isoforms of RNF19B (up to 4 have been reported), researchers should select antibodies with epitopes unique to or shared between isoforms. Cross-reactivity with RNF19A (Dorfin), which shares structural similarities with RNF19B, should be evaluated. Finally, validation status in the specific application and cell type of interest is crucial - researchers should prioritize antibodies with published validation data in similar experimental systems .

What are the optimal fixation and permeabilization methods for RNF19B immunostaining?

For optimal RNF19B immunostaining, fixation and permeabilization methods should be carefully selected based on experimental goals. For preserving RNF19B's transmembrane structure in immunofluorescence applications, 4% paraformaldehyde fixation (10-15 minutes at room temperature) is generally recommended as it maintains protein crosslinking while preserving epitope accessibility. When studying RNF19B in granule membranes of NK cells, a gentle permeabilization using 0.1-0.2% Triton X-100 for 10 minutes is typically effective. For investigating RNF19B in the endoplasmic reticulum, digitonin (0.01-0.05%) can be used for selective permeabilization of the plasma membrane while leaving internal membranes intact. When co-staining for RNF19B and cytolytic granule contents (perforin, granzymes), methanol fixation (-20°C for 10 minutes) may provide better results for some antibody combinations. For detailed subcellular localization studies, particularly of membrane-integrated proteins like RNF19B, confocal microscopy following these optimized protocols will provide the highest resolution of localization patterns .

How can researchers troubleshoot weak or nonspecific signals when using RNF19B antibodies?

When troubleshooting weak or nonspecific signals with RNF19B antibodies, researchers should implement a systematic approach. For weak signals, first verify RNF19B expression in the specific cell type and condition - remember that resting NK cells and unstimulated macrophages express minimal RNF19B, so appropriate activation with cytokines (IFNβ, IL-2 for NK cells; IFNγ for macrophages) for optimal durations (4-12 hours) is essential. Antibody concentration should be optimized through titration experiments, and enhanced detection systems (HRP-polymer conjugates or tyramide signal amplification) can be employed for low-abundance detection. For nonspecific signals, more rigorous blocking protocols using a combination of serum, BSA, and commercial blocking reagents can reduce background. Pre-adsorption of antibodies with cell lysates from RNF19B-knockout cells can remove cross-reactive antibodies. Validation with multiple antibodies targeting different epitopes of RNF19B can confirm specificity of signals. If working with tissues, autofluorescence reduction techniques should be employed, particularly important for macrophage-rich tissues which often exhibit high autofluorescence .

What is the best methodology to study RNF19B-mediated ubiquitination of target proteins?

The optimal methodology to study RNF19B-mediated ubiquitination of target proteins involves a multi-technique approach. In-cell ubiquitination assays can be performed by co-expressing tagged versions of RNF19B, a potential substrate, and His-tagged ubiquitin, followed by denaturing purification of ubiquitinated proteins and Western blotting with substrate-specific antibodies. For endogenous interaction studies, cells can be treated with proteasome inhibitors (MG132) to stabilize ubiquitinated proteins, followed by immunoprecipitation with RNF19B antibodies and blotting for ubiquitin or specific substrates. To identify the type of ubiquitin linkage created by RNF19B, specialized antibodies that recognize specific ubiquitin linkages (K48, K63, etc.) should be used in immunoblotting. For in vitro confirmation of direct ubiquitination, reconstituted ubiquitination assays using purified components (E1, E2s like UbcH7/UbcH8, immunopurified RNF19B, and putative substrates) can determine if RNF19B directly ubiquitinates the target. Mass spectrometry analysis following immunoprecipitation of the substrate can precisely identify ubiquitinated lysine residues and quantify ubiquitination stoichiometry .

How might RNF19B antibodies be used to develop new diagnostic or therapeutic approaches?

RNF19B antibodies could be utilized to develop innovative diagnostic or therapeutic approaches by targeting its unique role in immune cell function. For diagnostics, monitoring RNF19B expression levels in peripheral blood NK cells and macrophages could serve as a biomarker for immune activation status in inflammatory conditions or during immunotherapy response. Since RNF19B is critically involved in cytolytic activity, antibody-based imaging of RNF19B expression or activation in tumor-infiltrating lymphocytes could provide insights into the functional state of anti-tumor immune responses. Therapeutically, developing antibody-drug conjugates or bispecific antibodies targeting RNF19B-expressing activated immune cells could potentially direct these cells to specific tissue sites or tumors. For research applications, antibodies that specifically recognize active conformations of RNF19B could help distinguish between inactive and catalytically active forms, providing new tools to monitor E3 ligase activation in real-time during immune responses .

What novel techniques could enhance the specificity and sensitivity of RNF19B detection in complex samples?

Several emerging techniques could enhance specificity and sensitivity of RNF19B detection in complex samples. Proximity extension assays (PEA) could be developed using pairs of RNF19B antibodies conjugated to DNA oligonucleotides, providing ultra-sensitive detection in small sample volumes. Single-molecule array (Simoa) technology could enable detection of RNF19B at femtomolar concentrations in complex biological samples. For improved spatial resolution in tissues, multiplexed ion beam imaging (MIBI) or imaging mass cytometry (IMC) with metal-conjugated RNF19B antibodies could provide simultaneous detection of multiple proteins while preserving tissue architecture. CRISPR-based tagging of endogenous RNF19B with small epitope tags could allow for highly specific antibody detection without overexpression artifacts. Finally, conformation-specific nanobodies that recognize distinct structural states of RNF19B could help distinguish between active and inactive forms in situ, providing functional rather than just expression-level information .

How can antibody-based approaches be combined with other technologies to elucidate the temporal dynamics of RNF19B function?

To elucidate the temporal dynamics of RNF19B function, antibody-based approaches can be combined with several cutting-edge technologies. Live-cell imaging using anti-RNF19B nanobodies fused to fluorescent proteins could track RNF19B localization in real-time during immune synapse formation. Optogenetic tools combined with conformation-specific antibodies could allow researchers to trigger RNF19B activation with light and then monitor subsequent protein interactions and ubiquitination events. For temporal proteomics, antibody-based purification of RNF19B complexes at different time points after immune cell activation, followed by mass spectrometry, could reveal dynamic changes in protein interactions. Time-resolved FRET sensors incorporating RNF19B antibody fragments could detect conformational changes upon activation. Single-cell sequencing combined with antibody-based cell sorting for RNF19B expression levels could correlate transcriptional profiles with protein expression during immune cell activation. Finally, CRISPR activation/inhibition systems controlled by temporal regulators could modulate RNF19B expression at precise time points, with antibody-based detection methods monitoring downstream effects .